RxDoctor Payments DataLook up a doctor →

Damian Grovas Abad, MD

Interventional Cardiology · San Juan, PRNPI 1992900849

Payments from drug & device makers

$497,962in general payments, 2019–2025

Across 770 payments — averaging $646.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$323K
  • Boston Scientific$98K
  • Medtronic$60K
  • Terumo Medical Corporation$15K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$499
  • AstraZeneca$314
  • plus $987 from 11 others

What the payments were for

  • Consulting fees$271,39955%
  • Speaking & faculty fees$198,10040%
  • Travel & lodging$11,8392%
  • Food & beverage$16,5853%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$497,962 in reported general payments places this provider in the 95th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$33,003
Medicare patients
53
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban99$61,407
EliquisApixaban32$23,719
Cilostazol454$11,137
ClopidogrelClopidogrel Bisulfate947$8,312
BrilintaTicagrelor15$6,806
Atorvastatin Calcium129$1,223
Enalapril Maleate29$795
Chlorthalidone35$721
Acetazolamide11$579
Amlodipine Besylate66$526
Metoprolol Succinate41$506
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$459
Ezetimibe31$430
Losartan Potassium45$407
Isosorbide Mononitrate ErIsosorbide Mononitrate36$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$177$61,40799 claims
AstraZenecaBrilinta$314$6,80615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →